On April 11, 2016, Bob Coughlin, President and CEO of MassBio, and Glenn Batchelder, Executive Chair of XyloCor Therapeutics and immediate Past Chair of the MassBio Board of Directors testified on Senate Bill 1048 at the State House.
The bill is sponsored by State Senator Mark Montigny, Vice Chair of the Joint Committee on Health Care Financing. It would require manufacturers to disclose information related to the price of those drugs, including marketing and research costs. The bill would also allow the Massachusetts Health Policy Commission (HPC) to cap drug prices.